April 28, 2022
Press Release
Eiken Chemical Co., Ltd.
Representative: Tsugunori Notomi, President & CEO
Securities code: 4549 (TSE Prime)
Contact:Hajime Watari, Senior Vice President &Executive Officer(TEL: +81-3-5846-3379)

Formulation of EIKEN ROAD MAP 2030 and the New Medium-Term Management Plan
To respond to the unfolding changes in its business environment and operate from a perspectiveof sustainable management, the Eiken Group has revamped its existing management framework,
EIKEN ROAD MAP 2019. The road map is redefined as EIKEN ROAD MAP 2030, with 2030as the target year for its fulfillment.
The slogan for the Group's vision for 2030 is “Beyond the Field: Team × Challenge.” Under this slogan,we aim to achieve three objectives: To energize the skillset of each and every employee so that all
employees can broaden their domain of activity; to give rise to fresh possibilities by gathering
those individuals with their enhanced capabilities and taking them beyond their respective
domains to take on challenges as a team; and to step beyond existing business domains to inspire
innovation in medical processes, thereby building the future of testing.

EIKEN ROAD MAP 2030 identifies the Group’s existing business domains as its core businesses
while specifying three areas as key business fields: Contribution to the prevention and treatmentof cancer; Contribution to the eradication and control of infectious diseases; and Provision ofproducts and services that play a valuable role in health management. In the field of cancer, wewill focus on areas that are more directly related to treatment, while in the field of infectious
diseases, we will focus on establishing simpler testing technologies. In the field of healthcare, theGroup will expand its products and services to serve the needs of remote diagnosis and hometesting.
With a view to establishing a sustainable society, the Group has identified 11 materialities (keyissues) for priority response and is deploying detailed action plans for each. We believe that
contributing solutions to social issues in this way will further bolster our corporate value and leadto the achievement of a sustainable society.

1．EIKEN ROAD MAP 2030
Vision for the Medium-to-Long Term
■ Contribution to the prevention and treatment of cancerThe Eiken Group concentrates its efforts on the diagnostic business (prevention and earlydetection). This focus has enabled the Group to contribute to lowering the cancer death rate,particularly in colorectal cancer, by constructing a global screening program and enabling theearly detection of cancer. However, the cancer treatment field has other needs as well. Cancer
treatment can be ruinously expensive, and choosing the right treatment is paramount. To serve
these treatment needs, the Group aims not only to prevent cancer but also to develop
comprehensive testing systems with which to select therapeutic agents and judge the efficacyof treatments. In this way the Eiken Group is committed to reducing the death rate from cancer.

- 1 -■ Contribution to the eradication and control of infectious diseases
To grapple with threatening infectious diseases, the Eiken Group will expand its lineup ofrelated products and deploy genetic testing systems for tuberculosis, malaria and otherinfectious diseases worldwide. By developing infection-diagnostic systems that are simpler andfaster than previous diagnostic methods, the Group will contribute to improved access tohealthcare.
■ Provision of products and services that play a valuable role in health management
To extend people’s healthy lifespan, the Eiken Group will advance into the field of mobile
health, diversifying into remote diagnostics and home testing. Ultimately, the Group aims todevelop monitoring systems that stay close to people’s lives, providing information about theirhealth condition before they realize they need it.
Financial Targets (FY2030)
Index

TargetGrowthNet sales

Profitability

Overseas sales asshare of total
Operating income
marginReturn on equity(ROE)

Capital efficiency

JPY 75 billion
40% or greater
20% or greater
15% or greaterNon-financial Targets
As a Group whose mission is to protect the health of people worldwide, the Eiken Group isaddressing issues not only of healthcare but also of the environment, society and governance. For
each materiality, the Group sets key performance indicators (KPIs)* and monitors its progress
toward achieving them. In addition to tracking its performance on the KPIs, the Eiken Group reflects
this performance in its evaluation of executive officers’ performance and in their remuneration.

*Materialities and KPIs: https://www.eiken.co.jp/uploads/Materialities&KPIs_220428_1.pdf

2．Medium-Term Management Plan (FY2022–FY2024)
The current Medium-Term Management Plan is the first such Plan aimed at achieving EIKENROAD MAP 2030 and the Group’s growth strategy for the three years to March 31, 2025. This Plan
outlines key measures in accordance with the vision of EIKEN ROAD MAP 2030 and responds tothe currently accelerating paradigm shift in healthcare. In addition, the Plan aims to advance the- 2 -establishment of a management platform, promote personnel-focused management, enhance
employee satisfaction and motivation, furnish an environment that fosters innovation and boost
sustainable growth with steady improvement in profitability.
Principal Fields and Key Measures

Establishing a Management Platform for Sustainable Growth■ Human resources strategy
The Group is shifting to a wage system that focuses on job responsibilities and expertise andan evaluation system that brings out teamwork and challenges employees to pursue
employee satisfaction and meaningful work
■ Structural reform
Based on a common understanding that our business field is the global market, the Groupis optimizing business processes and overhauling its systems with a view to speeding up
decision-making.
■ IT strategy
The Group is actively introducing AI and robots, advancing DX in products and services anda wide range of business processes.
■ Financial strategy
By setting targets for cash conversion cycles, the Group is improving funding efficiency forbusiness investment and diversifying its fundraising.
■ Governance
The Group is strengthening its measures on ESG, with the aim of ensuring sound managementthat improves long-term corporate value. In addition, the Group is advancing proactive IR andPR with high transparency, for example through the publication of integrated reports.

- 3 -Financial Targets (FY2024)
IndexTargetGrowthNet sales

Profitability

Overseas sales asshare of total
Operating income
marginReturn on equity(ROE)

Capital efficiency

JPY 43.5 billion
25.8%
14.4%
9.2%

Disclaimer
Future-oriented statements in this document, including descriptions of plans, forecasts and strategies,
are based on information available to Eiken Chemical Co., Ltd. and assumptions that the Company
judges to be reasonable at the time of publication. These statements do not constitute promises ofperformance in any way. Actual business and other results are subject to change due to a wide rangeof factors.

- 4 -